title: Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
abstract: Peroxisome proliferator-activated receptor-alpha is widely distributed in the vasculature where it is believed to exert pleiotropic antiatherogenic effects. Its role in the regulation of blood pressure is still unresolved; however, some evidence suggests that it may affect the renin-angiotensin system. We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM). This is a model of hypertension and atherosclerosis because of high angiotensin II and aldosterone levels as a result of the transgenic expression of the entire human renin-angiotensin system. Making the THM animals deficient in Peroxisome proliferator-activated receptor-alpha (THM/PPARKO) totally abolished hypertension and myocardial hypertrophy. This was accompanied by a reduction in plasma human active renin in THM/PPARKO mice compared with THM animals from 3525+/-128 mU/L to 1910+/-750 mU/L (P<0.05) and by a normalization of serum aldosterone (1.6+/-0.29 nmol/L versus 3.4+/-0.69 nmol/L; P=0.003). In the THM/PPARKO mice, the extent of atherosclerosis at the aortic sinus after a 12-week period on an atherogenic diet was decreased by >80%. In addition, the spontaneous formation of foam cells from peritoneal macrophages, a blood pressure-independent event, was reduced by 92% in the THM/PPARKO mice, suggesting protection from the usual oxidative stress in these animals, possibly because of lower prevailing angiotensin II levels. Finally, chronic fenofibrate treatment further elevated blood pressure in THM animals but not in THM/PPARKO animals. Taken together, these data indicate that peroxisome proliferator-activated receptor-alpha may regulate the renin-angiotensin system. They raise the possibility that its activation may aggravate hypertension and hasten atherosclerosis in the context of an activated renin-angiotensin system.
authors.affiliation: Institute of Endocrinology, Metabolism and Hypertension, Aviv Sourasky Medical Center, Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel. karentor@tasmc.health.gov.il
authors.forename: Karen M
authors.initials: KM
authors.lastname: Tordjman
authors.forename: Clay F
authors.initials: CF
authors.lastname: Semenkovich
authors.forename: Trey
authors.initials: T
authors.lastname: Coleman
authors.forename: Rachel
authors.initials: R
authors.lastname: Yudovich
authors.forename: Stella
authors.initials: S
authors.lastname: Bak
authors.forename: Etty
authors.initials: E
authors.lastname: Osher
authors.forename: Michal
authors.initials: M
authors.lastname: Vechoropoulos
authors.forename: Naftali
authors.initials: N
authors.lastname: Stern
mesh_terms: D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000235:genetics / Q000378:metabolism; D000818:Animals; D050197:Atherosclerosis / Q000235:genetics* / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects / Q000235:genetics; D006332:Cardiomegaly / Q000235:genetics / Q000517:prevention & control; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D011345:Fenofibrate / Q000494:pharmacology; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000235:genetics* / Q000517:prevention & control*; D000960:Hypolipidemic Agents / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D047493:PPAR alpha / Q000819:agonists / Q000172:deficiency* / Q000235:genetics; D012083:Renin / Q000097:blood / Q000235:genetics; D012084:Renin-Angiotensin System / Q000235:genetics
chemical_list: D000960:Hypolipidemic Agents; D047493:PPAR alpha; D000804:Angiotensin II; D000450:Aldosterone; D012083:Renin; D011345:Fenofibrate